Pivot Bio, Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Pivot Bio, Inc. is one of 227 Biotech / Pharma companies tracked from Berkeley. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Pivot Bio is dedicated to supporting farmers with products that optimize crop production through specific nitrogen delivery.

Pivot Bio is dedicated to supporting farmers with products that optimize crop production through specific nitrogen delivery. Perhaps no pursuit is more noble than that of a farmer. Producing the food, fuel and products we depend on is all in a day’s work for farm families worldwide. Pivot Bio is dedicated to supporting farmers with products that optimize crop production through specifically timed and placed nitrogen delivery. Together, we are working toward a future that is more efficient, profitable, predictable, safe and sustainable for farmers and the planet. A catalyst for positive change, Pivot Bio brings partners together in pursuit of a sustainable future for agriculture. Pivot Bio microbial nitrogen changes everything, complementing a farmer’s fertilizer management plans by delivering nitrogen directly to the plant’s roots at the right time. Pivot Bio’s microbial nitrogen puts nitrogen where the plant needs it so that it’s there when the plant needs it. Our gene-edited microbes convert nitrogen from the atmosphere into ammonia directly on the plant’s root system. As long as a plant has roots, it has access to Pivot Bio’s nitrogen source. Pivot Bio products help ensure crops

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 100% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Pre-Seed$750K2014-10-22
   • First recorded raise — entered as Pre-Seed.
   • 1 investor on this round.
2. Series B$16.0M2016-01-13
   • Raised 15 mo later, in step with the ~15 mo sector norm.
   • Round 21.3× larger than the prior — scaling up.
   • Switched to Rule 506(b) (was Rule 506(c)).
   • 10 investors on this round.
3. Series A$8.1M2016-01-13
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.0× smaller than the prior — bridge or down round.
   • 4 investors on this round.
4. Series C$71.3M2018-09-13
   • Raised again after 32 mo — slower than the ~15 mo sector norm.
   • Round 8.8× larger than the prior — scaling up.
   • 15 investors on this round.
5. Series C$100.0M2020-01-06
   • Raised 16 mo later, in step with the ~15 mo sector norm.
   • Round 1.4× larger than the prior — scaling up.
   • 13 investors on this round.
6. Growth/Late$434.5M2021-06-28
   • Raised 18 mo later, in step with the ~15 mo sector norm.
   • Round 4.3× larger than the prior — scaling up.
   • 19 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Pivot Bio, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Pivot Bio, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Pivot Bio, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.